罗氏Roche和Labcyte整合Echo和LightCycler系统以增加基于qPCR的RNA/DNA分析性能

美国加州Sunnyvale2011年12月6日电：Roche和Labcyte公司将围绕高速、最小化的定量PCR（qPCR）进行合作，来监控治疗领域中成千上万的基因的表达。

Roche的RealTime Ready Cell Lysis Kit能在细胞溶菌液中直接进行基因表达，与Echo声波移液设备（Echo liquid handler）和Labcyte新开发的组织培养微孔板合用，研究者可以极大程度的简化高通量的qPCR分析。此过程可通过Labcyte公司的Access全自动微孔板预处理器（Access Workstation），将Echo liquid handler和LightCycler 480或LightCycler 1536仪器相整合，进行全自动操作。源于细胞的一步法基因表达现在可以精简成简单的自动化流程，显著提高生产力。

\"LightCycler 480和1536系统针对高通量基因检测、基因表达和基因变异分析设计。与市面上其他提供高于384孔板容量的高通量系统不同，LightCycler 1536允许单个孔到单个空的定位能力，并根据真实的qPCR性质进行优化。”qPCR/NAP系统的项目领导人Dr. Matthias Hinzpeter如是说。这个整合的平台可减少与基因表达图表相关的数据成本，将qPCR高效地融入药物研发的早期阶段。

\"Echo liquid handler使用声波能量转移精确到纳升级的样本、引物、探针和real-time PCR试剂。”Labcyte资深副主席Stephen Bates如是说。\"我们专利的声波移液技术消除了对枪头的需求，并完全消除了交叉污染的危险。我们Echo软件应用中对plate reformatting（微孔板重布局）和cherry picking（孔到孔转移）的简化，能满足对PCR布局灵活性的最大化需求，而没有固定的格式的限制。”

关于罗氏Roche
总部位于瑞士巴塞尔的Roche是以研发为主的健康科学、药学和诊断学领域的领头人。Roche是世界上最大的生物技术公司，在肿瘤学、病毒学、炎症、代谢和中枢神经系统都有各类药物。Roche还是体外诊断、基于组织的癌症诊断的世界领头人和糖尿病管理的先驱者。Roche的个体化医疗保健政策，旨在提供药品和诊断工具，以实实在在的改进患者的健康、生活质量和存活率。2010年，Roche在全球有超过8万名雇员，在R&D上的投资超过90亿瑞士法郎。集团销售额达475亿瑞士法郎。美国基因技术公司（Genentech）是Roche的全资子公司。Roche也拥有日本Chugai药物公司的大部分股权。更多信息，请参考：www.roche.com

关于Labcyte
总部位于美国加州Sunnyvale的Labcyte是一家生产革命性移液系统的全球性生物技术公司。Echo声波移液系统（Echo liquid handling systems）使用声波来精确移液。Labcyte仪器在全世界范围内被全部的前十大制药公司采用，其用户也包括其他中小型制药公司、生物技术公司、合同研究机构（CRO）和学术机构。Labcyte客户的工作范围遍布宽广的生物学领域，包括药物开发、基因组学、蛋白质组学、诊断学、影像质谱和活细胞转移。Labcyte拥有44个美国专利、8个欧洲专利、5个日本专利和1个中国专利，另外还有一些美国和国际专利正在申请中。更多信息，请参考：www.labcyte.com

Labcyte仪器的中国区总代理为：上海典奥生物科技有限公司。主要产品有：1）Echo非接触式纳升级声波移液系统（Echo Liquid Handler）；2）Access全自动微孔板预处理系统（Access Worksation）；3）POD 810全自动微孔板预处理系统（POD Automation Platform）；4）Portrait 630试剂反应多功能观测器；5）Deerac GX系列移液处理器；和6）Deerac LX 系列试剂分液器等。

Roche and Labcyte Integrate Echo and LightCycler Systems to Increase Performance of qPCR-based RNA/DNA Analyses

SUNNYVALE, Calif., Dec 06, 2011 (BUSINESS WIRE) -- Roche and Labcyte Inc. will cooperate around high-speed, miniaturized quantitative PCR (qPCR) to monitor the expression of tens to thousands of genes for therapeutic research.

The RealTime ready Cell Lysis kit from Roche enables gene expression directly from cell lysates. Coupled with Echo(R) liquid handlers and newly-released tissue culture microplates from Labcyte, researchers can greatly simplify high-throughput qPCR analyses. This process can be fully automated using the Access(TM) Workstation from Labcyte which integrates the Echo liquid handler with either the LightCycler 480 or LightCycler 1536 Instrument. Gene expression profiles derived in a one-step process directly from cells can now be streamlined into a simple automated workflow, significantly increasing productivity.

\"The LightCycler 480 and 1536 Systems are designed for high-throughput gene detection, gene expression, and genetic variation analysis. Unlike other high throughput systems on the market that offer greater than 384 well capability, the Lightcycler 1536 allows for individual well to well addressability and optimization due to its true qPCR nature,\" said Dr. Matthias Hinzpeter, Project Leader qPCR/NAP Systems. \"This integrated platform reduces data costs associated with gene expression profiling, allowing efficient incorporation of qPCR into the early stages of drug discovery.\"

\"The Echo liquid handlers use acoustic energy to transfer precise nanoliter volumes of samples, primers, probes and real-time PCR reagents,\" said Stephen Bates, Labcyte Senior Vice President. \"Our patented acoustic dispensing eliminates the need for pipette tips and completely removes the risk of cross contamination. The simplicity of plate reformatting and cherry picking features in our Echo software applications suite maximizes PCR layout flexibility without fixed format constraints.\"

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the worlds largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roches personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com

About Labcyte
Labcyte, a global biotechnology tools company headquartered in Sunnyvale, California, is revolutionizing liquid handling. Echo liquid handling systems use sound to precisely transfer liquids. Labcyte instruments are used worldwide by all ten of the top ten pharmaceutical companies, as well as by small to mid-size pharmaceutical companies, biotechnology firms, contract research organizations and academic institutions. Labcytes customers work across a wide spectrum of biology including drug discovery, genomics, proteomics, diagnostics, imaging mass spectrometry and live cell transfer. Labcyte has 44 U.S., 8 European, 5 Japanese and 1 Chinese patents with additional U.S. and international filings. For more information, visit www.labcyte.com

For life science research only. Not for use in diagnostic procedures.
LIGHTCYCLER and REALTIME READY are trademarks of Roche.
Echo and Access are trademarks of Labcyte Inc.
All other product names and trademarks are the property of their respective owners.

Labcyte_Roche_Gene_Expression_PR.pdf

地址：上海浦东新区东靖路1831号3楼301室 
联系人：刘映薇
电话：021-58605185-822
传真：021-58901159
Email：marketing@tekon.com.cn